Year: 2015
Type: article
Abstract: Toll-like receptor 7 (TLR7) senses microbial-derived RNA but can also potentially respond to self-derived RNA. To prevent autoimmune responses, TLR7 is thought to localize in endolysosomes. Contrary to this view, we show here that TLR7 is present on the cell surface of immune cells and that TLR7 responses can be inhibited by an anti-TLR7 antibody. The anti-TLR7 antibody is internalized with TLR7 and accumulates in endolysosomes as an immune complex. TLR7 responses in dendritic cells, macrophages and B cells are all inhibited by the anti-TLR7 antibody. Furthermore, the anti-TLR7 antibody inhibits in vivo cytokine production induced by a TLR7 ligand. Spontaneous TLR7 activation in Unc93b1(D34A/D34A) mice causes lethal inflammation. Progressive inflammation such as splenomegaly, thrombocytopenia and chronic active hepatitis are ameliorated by anti-TLR7 antibody treatment. These results demonstrate that cell surface TLR7 is a promising target for therapeutic intervention in autoimmune diseases.
Source: Nature Communications
DOI: 10.1038/ncomms7119
Institutions: Institute of Medical Science, The University of Tokyo, The University of Tokyo, Japan Society for the Promotion of Science, Daiichi-Sankyo (Japan), Kōchi University, Okayama University, Japan Science and Technology Agency, Tohoku University, Institute of Development, Aging and Cancer, Tohoku University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
Awards: Novel regulatory mechanism of TLR7/8 by ssRNA, Search for new molecules controlling the response of nucleic acid-sensing TLRs, Molecular basis underlying Toll-like receptor logistics, Structural studies of nucleic acid sensing Toll-like receptors, G7879866177, 自然免疫応答による抗原提示プラットホームの活性化とその分子基盤の解明
OpenAlex ID: W2055527896
